Anemia developed after birth without fetal lethality
Although the development of erythropoietin (Epo) -related drugs requires the existence of animal models for disease states such as renal anemia, Epo knockout mice are not suitable as a model because of the embryonic lethality and the large inter-experiment/inter-individual differences in the anemia state in the models produced by surgery/drug treatment. The present invention relates to transgenic mice (I-SAM) that have overcome these problems. In I-SAM, the endogenous Epo gene is homologically knocked out by insertion of the GFP gene, and a region from 3.3kbp upstream to 4.5kbp downstream of the Epo gene transcription start point (Transgene) is introduced. In I-SAM before birth, transgene-derived Epo is expressed in the liver, etc., and there is no embryonic lethality. After birth, transgene does not express Epo because it has no transcriptional activity in the major Epo-producing tissues, such as the kidney, and there is anemia. I-SAM has the following characteristics. ・Epo knockout but not embryonic lethality ・Stably develop high levels of anemia after birth ・Have normal renal function ・Have tissue Epo-producing cells labeled with GFP ・Have a long lifespan and can reproduce by mating
Inquire About This Product
basic information
For more details, please contact us or refer to the PDF.
Price range
Delivery Time
Applications/Examples of results
For details, please contact us or refer to the PDF.
catalog（1）
Download All Catalogs
Company information
The revenue generated from technology transfer is reinvested as new research funding for universities and researchers, and is utilized to create further research outcomes. To ensure the smooth operation of this cycle, known as the "Intellectual Creation Cycle," we will vigorously promote technology transfer. The types of seeds we handle include patents, know-how, databases, and programs. We have established a collaborative framework by signing basic technology transfer agreements with the following universities (as of June 1, 2025): Tohoku University, Hirosaki University, Iwate University, Akita University, Fukushima University, Yamagata University, Tohoku Gakuin University, Iwate Medical University, Fukushima Medical University, Aizu University, Miyagi University, Hokkaido University, Muroran Institute of Technology, and Showa Medical University.
